Streetbeat News

LGVN

Longeveron Inc.

https://www.longeveron.com

Industry

Biotechnology

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Open

2.15

Mkt cap

32M

Volume

318K

High

2.26

P/E Ratio

-0.25

52-wk high

23.90

Low

2.14

Div yield

N/A

52-wk low

0.77

Trading for LGVN was halted and then resumed at 8:55 AM ET, following an update on its status.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:55 pm

Trading for LGVN was halted at 7:50:00 p.m. ET due to pending news. This action indicates that significant information affecting the company is about to be released, which could impact its stock price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:50 pm

Healthcare stocks experienced significant movements in Wednesday's intraday session. XTL Biopharmaceuticals led the gainers with a 95.8% increase, while Lifecore Biomedical topped the losers, declining by 31.4%. Other notable movers include Etao International, Annovis Bio, and Taysha Gene Therapies, which reported Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 5:31 pm

In Tuesday's after-market session, several healthcare stocks showed significant movement. Etao International Co led the gainers with a 249.4% increase, while Aquestive Therapeutics experienced the largest decline among the losers at 11.4%. Taysha Gene Therapies reported Q4 earnings, contributing to a 29.36% rise in its stock. Other notable movers include Moleculin Biotech, Turnstone Biologics, and Enveric Biosciences on the gainers' side, and Trxade Health, Ontrak, and Virpax Pharmaceuticals among the losers.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 9:34 pm

Longeveron's Board has approved a 1-for-10 reverse split of its Class A common stock, effective March 26, 2024, at 11:59 p.m. Eastern Time. The stock will trade on a split-adjusted basis under the ticker symbol 'LGVN' on The Nasdaq Capital Market starting March 27, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 8:02 pm

Longeveron (NASDAQ:LGVN) reported Q4 earnings with an EPS of $-0.25, missing estimates by -19.0% and showing a revenue decrease of $58 thousand from the previous year. This follows a pattern of missed EPS estimates in previous quarters, which has historically led to a drop in share price.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:40 pm

Longeveron (NASDAQ:LGVN) reported Q4 earnings with a per-share loss of $(0.25), missing the $(0.21) estimate, and sales of $63.00K, missing the $210.00K estimate. This represents a 19.05% increase in per-share losses and a 70% miss in sales estimates compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:35 pm

Numerous companies are scheduled to report their earnings on February 27, 2024, covering a wide range of industries from technology and healthcare to energy and financial services. The report includes a mix of expected quarterly losses and earnings, highlighting the diverse financial health and performance outlooks within the corporate landscape.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 10:01 am

Longeveron (NASDAQ:LGVN) is scheduled to release its quarterly earnings report on February 27, 2024, with an expected EPS of $-0.21. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Historical performance shows a mixed reaction to past earnings reports, with share prices fluctuating based on actual EPS versus estimates. Currently, shares are trading at $0.518, down 85.06% over the last year, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 9:00 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. SINTX Techs (SINT) saw the largest gain, with shares up 79.8%, while Applied DNA Sciences (APDN) had the largest decline, dropping 30.0%. Other notable gainers include Phio Pharma (PHIO), Trinity Biotech (TRIB), NexImmune (NEXI), Vicarious Surgical (RBOT), and Longeveron (LGVN). On the losing side were Innovative Eyewear (LUCY), Synaptogenix (SNPX), DermTech (DMTK), Assure Holdings (IONM), and OpGen (OPGN).

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.